Targocid IM/IV Injection 200mg

Product Name: Targocid IM/IV Injection 200mg 

Product Form: Injection

Pack Size: 1s

Manufactured By: Sanofi

Used For:

• Teicoplanin is a glycopeptide antibiotic primarily used to treat serious bacterial infections caused by Gram-positive bacteria, including:
  • Methicillin-resistant Staphylococcus aureus (MRSA) infections.
  • Skin and soft tissue infections, especially those caused by Staphylococcus aureus or Streptococcus.
  • Bacterial endocarditis (infection of the heart valves).
  • Bone and joint infections, including osteomyelitis.
  • Pneumonia caused by resistant bacteria.
  • Sepsis and infections in patients with weakened immune systems (e.g., cancer patients).

Side Effects:

• Common Side Effects:
  • Pain or irritation at the injection site (when administered intravenously).
  • Fever, chills, or skin rash.
  • Nausea and diarrhea.
• Serious Side Effects:
  • Ototoxicity (damage to the inner ear) and nephrotoxicity (kidney damage), especially if given in high doses or for prolonged periods. Hearing loss or ringing in the ears (tinnitus) should be reported immediately.
  • Red man syndrome (flushing, rash, and hypotension), which can occur when the infusion rate is too fast. It is often treated by slowing the infusion.
  • Severe allergic reactions, including anaphylaxis (swelling, difficulty breathing, hives, and dizziness).
  • Thrombophlebitis (inflammation of the veins), particularly at the injection site.
  • Blood disorders, including neutropenia (low white blood cell count) and thrombocytopenia (low platelet count).
• Other Effects: May cause fever, headache, or abdominal pain in some individuals.

Precautions:

• Kidney Function: Teicoplanin is primarily excreted by the kidneys, so it should be used with caution in individuals with renal impairment. Kidney function should be monitored during treatment, and dose adjustments may be required.
• Hearing and Balance: Due to the risk of ototoxicity, hearing and balance should be monitored, especially during prolonged use or high doses.
• Infusion Rate: To minimize the risk of red man syndrome, the infusion rate should be controlled carefully. This reaction is often prevented by administering the drug slowly over a longer period of time.
• Pregnancy and Breastfeeding: Teicoplanin is classified as Category C in pregnancy, meaning it should be used during pregnancy only if the benefits outweigh the risks. It is excreted in breast milk, so breastfeeding mothers should consult their doctor before using teicoplanin.
• Drug Interactions: Teicoplanin can interact with other nephrotoxic or ototoxic drugs, including aminoglycosides (e.g., gentamicin) and loop diuretics (e.g., furosemide). These drugs should be used cautiously in combination with teicoplanin, and monitoring of kidney function and hearing is advised.